COMPOSITIONS AND METHODS FOR BIOLOGICAL SAMPLE STORAGE
    92.
    发明申请
    COMPOSITIONS AND METHODS FOR BIOLOGICAL SAMPLE STORAGE 审中-公开
    用于生物样品储存的组合物和方法

    公开(公告)号:WO2010132508A2

    公开(公告)日:2010-11-18

    申请号:PCT/US2010/034454

    申请日:2010-05-11

    摘要: Compositions and methods are disclosed for substantially dry storage at ambient or elevated temperatures of biological samples such as nucleic acids,, proteins and cells in a form from which the samples can be substantially recovered, using a dissolvable or dissociable dry storage matrix comprising a borate composition and a stabilizer as disclosed, such as any of a number of zwitterionic stabilizers.

    摘要翻译: 公开了组合物和方法,用于在环境或升高的温度下在生物样品例如核酸,蛋白质和细胞中基本上干燥储存,所述生物样品可以使用可溶性或可离解的干储存基质,其可以基本上回收样品,所述可溶性或可离解的干储存基质包含硼酸盐组合物 和所公开的稳定剂,例如许多两性离子稳定剂中的任何一种。

    17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
    97.
    发明申请
    17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS 审中-公开
    17-ACETAMIDO-4-AZASTEROID衍生物作为雄激素受体调节剂

    公开(公告)号:WO2005005606A2

    公开(公告)日:2005-01-20

    申请号:PCT/US2004020539

    申请日:2004-06-25

    CPC分类号: C07J73/005

    摘要: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    摘要翻译: 结构式I的化合物是以组织选择性方式的雄激素受体(AR)的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病,包括骨质疏松症,骨质减少,糖皮质激素诱导的骨质疏松症,牙周病,骨折,骨重建后的骨损伤 手术,肌营养不良,虚弱,老化的皮肤,男性性腺机能减退,女性绝经后症状,动脉粥样硬化,高胆固醇血症,高脂血症,肥胖,再生障碍性贫血和其他造血障碍,炎症性关节炎和关节修复,HIV消耗,前列腺癌,良性前列腺增生 ),癌症恶病质,阿尔茨海默病,肌营养不良症,认知衰退,性功能障碍,睡眠呼吸暂停,抑郁症,卵巢早衰,以及自身免疫疾病,单独或与其它活性剂组合。